Jfl Life Sciences Limited — Results, 01-07-2025: Reply to Clarification- Financial results

JFL Life Sciences has announced a board meeting on May 19, 2025, which approved the audited financial results for the quarter and half-year ended March 31, 2025. The audit report was issued with an unmodified opinion, indicating a clean bill of health.

For the 6 months ended March 31, 2025, total income stood at Rs. 32.99 Cr (3,299.21 lakhs), up from Rs. 27.75 Cr in the same period last year. Operating expenses largely increased in line with revenue, with cost of materials consumed rising to Rs. 23.95 Cr. Finance costs were contained at Rs. 0.45 Cr. The company reported a profit before tax of Rs. 1.68 Cr for the half-year, a significant improvement from Rs. 0.25 Cr in the previous year.

For the full financial year ended March 31, 2025, the company posted total income of Rs. 82.05 Cr, with a profit before tax of Rs. 6.68 Cr, compared to previous year’s Rs. 46.55 Cr and profit of Rs. 3.79 Cr respectively. Earnings per share (EPS) for the year were Rs. 1.00 (face value Rs. 10).

Balance sheet highlights include total assets of Rs. 71.91 Cr as of March 2025, up from Rs. 56.71 Cr a year ago. Equity share capital remains at Rs. 32.99 Cr, while other equity increased to Rs. 39.45 Cr. Total liabilities rose to Rs. 33.96 Cr from Rs. 20.43 Cr, reflecting modest growth in borrowings and provisions.

Cash flow from operations was robust at Rs. 5.24 Cr. Investing activities showed a net cash outflow (mainly capex), while financing activities reflected repayment of borrowings and dividend payments. The company’s cash and cash equivalents closed at Rs. 0.03 Cr for the year.

Notably, JFL Life Sciences issued bonus shares in a 2:1 ratio during the period; the allotment has been completed with in-principle approval received post-balance sheet date.

Overall, the company demonstrated healthy top-line growth and improved profitability, backed by a stable balance sheet and positive cash flow dynamics.